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LIST OF ABBREVIATIONS 
PUFA Polyunsaturated Fatty Acid 
LCPUFA Long-Chain Polyunsaturated Fatty Acid 
DHA Docosahexaenoic Acid 
EPA Eicosapentaenoic Acid 
ARA Arachidonic Acid 
EC Endocannabinoids 
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Human breast milk (HBM) is an extremely complex yet fascinating biofluid tailored to 
meet an infant’s nutritional requirements for development. Amongst the nutrients present in 
HBM, the long-chain polyunsaturated fatty acids (LCPUFAs) are of high importance due to the 
pivotal role they play in infant cognitive and visual development, and growth. In addition, the 
LCPUFAs are precursors to endocannabinoids (EC) which are endogenous lipid mediators. EC 
exert metabolic responses including appetite and food intake regulation, and they have been 
identified to play a role in establishing the suckling response of the newborn that is needed to 
nurse. Thus, we aimed to characterize and quantify the EC present in HBM, termed the EC 
metabolome (ECM). HBM samples were collected from two different populations, one in 
Guatemala (n = 26) and the other one in the United States (n = 24). We collected HBM at 
different lactation stages: transitional (2 weeks postpartum) and mature (4 weeks and 16-24 
weeks postpartum) milk. Using liquid chromatography-mass spectrometry analyses, we 
identified 15 members of the ECM in both lactation stages: arachidonoylethanolamine, 
palmitoylethanolamine, oleoylethanolamine, docosahexaenoylethanolamine, 
eicoapentaenoylethanolamine, eicosenoylethanolamine, arachidonoylglycerol, palmitoyglycerol, 
oleoylglycerol, docosahexaenoylglycerol, eicosapentaenoylglycerol, eiconenooylglycerol, 
arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid. Overall, members in the 
glycerol group were higher in concentration than those of the ethanolamide group. To date, the 
mechanisms of action and the role of the ECM in HBM and infant development are not fully 
understood. Data from the present study provides a foundation to develop future studies to help 





Endocannabinoid research has attracted considerable interest because of the physiological 
functions of these bioactive compounds and their possible therapeutic use in maintaining health.1 
The endocannabinoid metabolome (ECM) consists of different lipid mediators which are derived 
from fatty acids conjugated with either an ethanolamine or a glycerol group. Regarded as the 
gold standard, breast milk is a bioactive fluid that has a unique composition to meet infants’ 
needs throughout development. Recent research has demonstrated the presence of these 
biological signaling molecules, endocannabinoids and endocannabinoid-like compounds, in 
human breast milk. Endocannabinoids play a role in establishing the suckling response of the 
newborn by activating the oral-motor musculature needed for milk suckling. The established 
suckling response in turn supports maternal-infant bonding and maintains infant feeding 
behavior. 
To date, the mechanisms of action and the role of the ECM in breast milk and infant 
development are not fully understood. The present study has characterized and quantified the 
ECM in two different populations. The first population assessed corresponds to a cohort from 
Guatemala, a developing country, whereas the second population corresponds to a cohort in the 
United States representing a developed country. In this regard, we were able to evaluate how 
maternal nutritional status can affect the fatty acids and the ECM of breast milk. The present 
study will set the stage for developing hypotheses for future studies that will help to elucidate 









2.1 Human Milk and Lactation 
Recognized as the gold standard, with its unique composition, breast milk provides the 
infant with optimal nutrition needed in the minutes following birth and throughout development 
of the first year. According to Koletzko (2016), “milk can be characterized as an emulsion of 
milk fat globules in an aqueous liquid.”2 The American Academy of Pediatrics and the World 
Health Organization recommend exclusive breastfeeding of infants up to six months of age with 
continued breastfeeding along with complementary foods for up to two years of age or beyond.3,4 
According to the Center for Disease Control and Prevention,5 only 22.3% of infants in the United 
States are exclusively breastfed at six months with 51.8% of infants breastfed at six months and 
30.7% at 12 months but supplemented with formula. However, initiation rates for infants ever 
breastfed are 81.1% which demonstrates that mothers’ intent to breastfeed at least for the first 
days postpartum (one to two days) while at the hospital after delivery. Globally, only 38% of 
infants are exclusively breastfed during the first six months of life.6 The Baby-Friendly Hospital 
Initiative, which was launched in 1991 and sponsored by the World Health Organization (WHO) 
and the United Nations Children’s Fund (UNICEF),7 has helped to improve the national rates for 
breastfeeding by encouraging and recognizing hospitals and birth centers that offer an optimal 
level of care for lactation based on the Ten Steps to Successful Breastfeeding (Table 2.1). In 
addition, the WHO has issued the International Code of Marketing of Breast-Milk Substitutes to 
provide recommendations on the marketing of breast milk substitutes, feeding bottles, and teats 





Table 2.1. WHO/UNICEF Ten Steps to Successful Breastfeeding 
1. Have a written breastfeeding policy that is routinely communicated to all health care 
staff. 
2. Train all health care staff in skills necessary to implement this policy. 
3. Inform all pregnant women about the benefits and management of breastfeeding. 
4. Help mothers initiate breastfeeding within a half-hour of birth. 
5. Show mothers how to breastfeed, and how to maintain lactation even if they should be 
separated from their infants. 
6. Give newborn infants no food or drink other than breastmilk unless medically indicated. 
7. Practice rooming in - allow mothers and infants to remain together - 24 hours a day. 
8. Encourage breastfeeding on demand. 
9. Give no artificial teats or pacifiers (also called dummies or soothers) to breastfeeding 
infants. 
10. Foster the establishment of breastfeeding support groups and refer mothers to them on 
discharge from the hospital or clinic. 
Lactogenic Hormones 
Two main hormones facilitate and direct lactation: prolactin for milk production and 
oxytocin for milk ejection. Prolactin is further modulated by pituitary, ovarian, thyroid, adrenal, 
and pancreatic hormones.9 Following delivery of the placenta, progesterone levels decrease and 
prolactin levels increase, stimulating milk synthesis.10 The regulation of milk production is based 
on infant demand, with suckling stimulating the release of prolactin in response to nipple 
manipulation.9 Oxytocin, which facilitates delivery of the infant by causing the uterus to 
contract, facilitates milk ejection.9 Oxytocin is also released in response to sensory pathways 
when the mother sees, touches, hears, smells or thinks about the infant. On the other hand, 
release of oxytocin can be blocked by stress and fright.9,11 
Lactating Mammary Gland: Milk Production and Secretion 
The mammary gland meets three specific functions: synthesis, secretion, and delivery of 
milk to the infant. Mammary development starts as early as during fetal growth, reaching the 
height of development during the pregnancy-lactation cycle with involution following weaning.12 
Glandular and adipose tissues are the main components of the mammary gland, held together by 
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connective tissue, called Cooper’s ligaments11 (Figure 2.1). During pregnancy the breast gains 
approximately 0.75 pounds and becomes firm and full in preparation for lactation.13 Maternal 
requirements for energy increase during lactation with the breast using about 25% above the 
daily energy intake (based on 2,000 kcal/day) to produce milk.14 
Milk is produced in the alveoli and is released into the ducts. The nipple contains 
between 15 to 25 ducts that are used for milk delivery/transport.9 Contraction of myoepithelial 
cells cause the alveoli to release the milk to be ejected through the nipple.11,12  
 
Figure 2.1. Anatomy of the Lactating Breast.15 Figure on the left side represents a breast during 
pregnancy in preparation to produce milk. Figure on the right represents a breast that is 
producing milk postpartum. 
To summarize, the “milk ejection reflex” is an interplay between hormones that 
synthesize and release the milk following a cascade of events initiated by infant suckling which 
stimulates prolactin and oxytocin release from the pituitary gland, thus stimulating milk 
synthesis and secretion.16 Stimulation at the nipple in response to infant suckling causes nerve 
impulses to stimulate oxytocin release from the posterior pituitary that will act on the mammary 
gland causing myoepithelial cells to contract to eject milk from the alveoli into the ducts and 




Stages of Lactation 
Lactation encompasses three different stages: mammogenesis, lactogenesis, and 
involution. Mammogenesis refers to the mammary growth and differentiation of alveolar 
epithelial cells from fetal life through puberty, reaching its complete development following 
parturition.18 Lactogenesis refers to the initiation of lactation, milk secretion, until the breast 
stops producing milk following weaning which is referred to as involution when the mammary 
gland returns to a nonlactating state.12  
Lactogenesis is further divided into three stages: 
a. Lactogenesis I: in this stage, mammary tissue undergoes differentiation to change from a 
nonlactating to a lactating state. During pregnancy, alveolar epithelial cells differentiate 
into lactocytes that synthesize milk with accumulation of colostrum.12 High maternal 
circulating plasma concentrations of progesterone and estrogen halt secretion of milk.10 
b. Lactogenesis II: this stage is characterized by the onset of copious milk secretion 
following parturition.10 Blood flow increases, accompanied by oxygen and glucose 
uptake.9 
c. Lactogenesis III: this last stage facilitates maintenance of milk production until weaning.9 
Within a feeding, breast milk is further categorized as foremilk, the initial milk, and hindmilk, 
the last milk of a feed.19 
Breast Milk Composition 
New mothers are capable of producing milk that meets their infants’ needs throughout 
development. Milk composition changes from the first days following birth to about four weeks 
postpartum when lactation has been stablished. The three different stages of human milk 
following birth are: 
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a. Colostrum: this thick yellowish secretion is present for the first three to five days.12 It is 
high in protein,12 immunoglobulins, lactoferrin,10 oligosaccharides,20 and immune cells.21 
Colostrum boosts the infant’s immunological system and provides protection against 
infections. Andreas et al. (2015)22 proposed that the primary role of colostrum in infant 
health is immunological rather than nutritional. 
b. Transitional: this milk is produced from five days to about two to three weeks (14-21 
days) postpartum.12 The concentration of immunoglobulins, protein, and fat-soluble 
vitamins decrease while the lactose, fat, water-soluble vitamins, and total caloric content 
increase compared to colostrum.16 
c. Mature: the last stage is from three to four weeks postpartum until weaning occurs.12 
Table 2.2 indicates the predominant nutrients present in mature breast milk. Milk fat 
globule membrane proteins (mucins), whey proteins, and caseins comprise the three groups of 
the protein fraction,23 with the caseins present in higher concentrations compared to mucins and 
whey proteins.22 The predominant proteins are α-lactalbumin, lactoferrin, and secretory 
immunoglobulin A (sIgA) which with a wide array of other proteins exert antimicrobial, 
immunomodulation, and nutrient absorption roles which help in the development of the infant’s 
gastrointestinal tract. Soluble amino acids are present to support growth.23  
Lactose is the main carbohydrate present in breast milk16 and the least variable of the 
macronutrients.19 Lactose concentrations correspond to the high energy demands of the brain.22 
In mature breast milk, energy estimates range from 65 to 70 kcal/dL.19 Lipids are the major 
source of energy in breast milk. Triglycerides account for 98% of the lipid fraction2 and are the 
main source of energy in breast milk.24 Polyunsaturated fatty acids (PUFAs) account for 
approximately 21% of the total fatty acids present in breast milk.25 More specifically, for the 
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long-chain PUFAs (LCPUFAs) estimated levels worldwide are 0.32% for docosahexaenoic acid 
(DHA, 22:6n3) and 0.47% for arachidonic acid (ARA, 20:4n6) based on the total fatty acids.26  
Table 2.2. Breast Milk Composition in Mature Milk 
Nutrient Content (%) 
Watera 88.1 
Lactoseb 6.7 – 7.8 
Fatb 3.2 – 3.6 
Proteinb 0.9 – 1.2 
Othera 0.2 
aBallard and Morrow, 201319; bLawrence, 199416  
Many factors influence milk composition. Maternal factors including age, parity, body 
mass index, and diet, along with infant factors such as gestational age and birth weight, as well 
as time of the day and stage of lactation, among others, are known to modify breast milk. Fields 
et al. (2016)27 summarized the factors that may influence breast milk composition (Figure 2.2). 
Even during the same feeding, milk composition changes. For example, within a feeding, the fat 
content is highly variable, with higher concentrations in the last milk of a feed.19 The 
concentration of fatty acids in milk is directly related to maternal diet.24 Jensen et al. (2000)28 
compared three different sources of DHA supplementation (each providing about 200 mg/day) to 
lactating women from week two to week eight postpartum. It was determined that DHA content 
in breast milk increased with dietary supplementation from about 0.24% at baseline to about 
0.37% of total fatty acids at the end of the study. In another study by Hawkes et al. (2002),29 
lactating women were provided a supplement with either a placebo, 300 mg or 600 mg of 
DHA/day from three days to four weeks postpartum. It was found that DHA content of breast 
milk was increased in relation to DHA intake. Similarly, Sherry et al. (2015)30 provided lactating 
women with either a placebo, 200 mg or 400 mg of DHA/day for six weeks. DHA content of 
breast milk increased over the six weeks of intervention and was directly proportional to the 
amount of DHA provided in the capsules. DHA content in breast milk is determined by maternal 
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DHA intake mainly.31 Fatty acid concentrations in breast milk may even be influenced by dietary 
consumption of DHA and eicosapentaenoic acid (EPA, 20:5n3) during pregnancy.32 Therefore, 
the lipid fraction of breast milk is the most variable nutrient during lactation.22 Breast milk is 
dynamic in composition in order to meet infant’s needs throughout development. 
 
Figure 2.2. Factors Influencing Breast Milk Composition.27 This figure summarizes the factors 
that influence breast milk composition in addition to maternal-infant factors, including 
physiological and behavioral. 
Benefits of Breastfeeding 
a. Infant outcomes: 
To what extent the benefits of breastfeeding can be observed depends on the duration and 
exclusivity versus supplemented breastfeeding. For example, according to Ip et al. (2007)33 who 
evaluated the effects of breastfeeding in the short- and long-term for mother and child in 
developed countries, the incidence of otitis media was 23% lower in infants with any 
breastfeeding compared to infants fed infant formula only; exclusive breastfeeding for three to 
six months reduced the risk of otitis media by 50%. Further, reduction in the incidence of 
gastrointestinal tract infections was associated with any breastfeeding. Breastfeeding for four or 
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more months was associated with reduction in the risk of hospitalization secondary to respiratory 
diseases by 72%. A meta-analysis conducted by Thompson et al. (2017)34 showed that 
breastfeeding for at least two months was associated with protection against sudden infant death 
syndrome by 40% with an increased protection of 54% when infants were breastfeed for four to 
six months. Obesity rates are lower in breastfed infants suggesting that breastfeeding provides 
protection against developing childhood obesity later in life.35 Infants exclusively breastfed for 
four to six months are at lower risk of developing a nonspecific gastrointestinal infection.36 
Proteins, such as immunoglobulins, lysozyme, lactoferrin, etc., that are present in breast milk 
provide the infant with immunity and contribute in the development of the intestinal mucosa of 
the newborn, whereas other types of protein aid in the digestion and uptake of other nutrients in 
breast milk.37 Breastfeeding has also been associated with lowering the risk of developing 
asthma.38,39 
b. Maternal outcomes 
Research has shown that breastfeeding can provide benefits to the mother as well as the 
child. It can be protective against the development of breast cancer.40,41 Further, the Women’s 
Health Initiative42 reported a significant reduction in the incidence of hypertension, 
hyperlipidemia, cardiovascular disease, and diabetes in women who had a cumulative history of 
lactation for 12 to 23 months. The development of type 2 diabetes is less likely to occur in 
mothers who have exclusively breastfed their infants for one-three months.43 Lactational 
amenorrhea can act as a natural birth control if breastfeeding exclusively for six months.44 The 
role of breastfeeding and postpartum depression is still inconclusive.33 However, data have 
shown that multiparous, but not primiparous, women are at reduced risk of having postpartum 




Research conducted by Dr. Raphael Mechoulam in the 1960-1970s opened up a new area 
of research by isolating the main active component of Cannabis sativa, commonly known as 
marijuana, delta-9 tetrahydrocannabinol (Δ-9 THC).46,47 Research in this field has increased 
considerably over time although many roles, functions, and mechanisms of action remain to be 
understood. Following that early discovery, endogenous lipid ligands that bind to the same 
receptors as marijuana, ‘endocannabinoids’ (EC), were reported.48,49  
Endocannabinoids are lipophilic molecules derived from LCPUFAs.50 Two G-protein 
coupled receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), are responsible for the 
activation/deactivation of the EC.51 Cannabinoid receptor type 1 is present mainly in the central 
nervous system and CB2 is expressed predominantly in immune cells.52 
Arachidonylethanolamide (anandamide, AEA), was the first EC discovered in 1992 and it is the 
most thoroughly studied to date.48 Anandamide received its name from the Sanskrit word 
‘ananda’ that means superior bliss.53 Then, 2-arachidonoylglycerol (2-AG or AG) was identified 
in 1995.49 Both AEA and 2-AG are derived from ARA, an n-6 LCPUFA,54 conjugated with 
ethanolamine or glycerol, respectively. These molecules bind to CB1 and CB2 receptors, 
although with different affinities.55 Anandamide has been found to be a partial agonist of CB1, 
whereas 2-AG acts as a full agonist for both CB1 and CB2.56 The main enzymes involved in EC 
degradation are fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).57 The 
endocannabinoid system (ECS) encompasses the EC (AEA and 2-AG), the receptors (CB1 and 
CB2), and the enzymes involved in their metabolism (MAGL and FAAH). Figure 2.3 shows how 




Figure 2.3. The Endocannabinoid System as Drawn by Vemuri and Makriyannis, 2015.58 This 
figure represents the interaction of the endocannabinoid system between the post-synaptic and 
pre-synaptic neuron. Circled members represent the endocannabinoid system as discussed in this 
chapter: AEA, arachidonoylethanolamide; 2‐AG, 2‐arachidonoylglycerol; CB1, cannabinoid 
receptor 1; CB2, cannabinoid receptor; MAGL, monoacylglycerol lipase; and FAAH, fatty acid 
amide hydrolase. 
More recently, other endocannabinoid metabolites have been identified. A complete set 
of 15 metabolites has been termed the ‘endocannabinoid metabolome’ (ECM) (Figure 2.4) which 
can be defined as a set of endogenous signaling lipid mediators that interact directly or indirectly 
with the ECS.59,60 The ECM includes i) six members of the ethanolamide derivatives: AEA, 
palmitoyl ethanolamide (PEA), oleoyl ethanolamide (OEA), docosahexaenoyl ethanolamide 
(DHEA), eicosapentaenoyl ethanolamide (EPEA), and eicosenoyl ethanolamide (EEA); ii) six 
members of the glycerol derivatives: 2-AG, palmitoyl glycerol (PG), oleoyl glycerol (OG), 
docosahexaenoyl glycerol (DHG), eicosapenaenoyl glycerol (EPG), eicosenoyl glycerol (EG); 
and iii) three precursor LCPUFAs: ARA, DHA, and EPA. These metabolites are believed to 
interact with an ‘entourage effect’ meaning that metabolites exert a greater effect to support 
physiological responses by interacting with each other rather than in isolation or by increasing or 
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decreasing binding affinity to its receptors.61 Some of these metabolites do not bind to CB1 or 
CB2 or have little affinity for the receptors, but many exhibit cannabimimetic effects and act as 
endogenous modifiers and lipid mediators62 primarily to AEA and 2-AG. 
 
Figure 2.4. Chemical Structure of the Endocannabinoid Metabolome.63 Represented in this figure 
are: three long-chain polyunsaturated fatty acids, six ethanolamide-derivatives, and six glycerol-
derivatives. It can be observed that the structure of the endocannabinoids and endocannabinoid-
like metabolites resemble that of the precursor fatty acid. 
Mechanism of Action of Endocannabinoids 
 Endocannabinoids are synthesized on demand in response to stimuli, and they can act in a 
paracrine or autocrine fashion55; thus, they are not stored in cells. Upon membrane 
depolarization of the neuronal cell and Ca2+ influx into the cell, EC are released through 
facilitated diffusion from postsynaptic neurons to act as retrograde synaptic messengers on 
cannabinoid receptors located on presynaptic neurons53,60 (Figure 2.3). Once inside the cell, EC 
are metabolized by hydrolysis or oxidation.64 Metabolic enzymes, anabolic and catabolic, 
modulate the EC tone50 and are Ca2+ sensitive.65 
Physiological Roles of Endocannabinoids 
 Endocannabinoids play a role in different metabolic functions including regulation of 
immune and inflammatory responses,66 reproduction,57,67 protection against cancer,68 and 
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regulation of appetite and food intake.64 Table 2.3 summarizes some of the physiological roles of 
members of the ECM.  
 Endocannabinoids are involved in modulating the inflammatory response through the 
same pathways as eicosanoids which are also derived from LCPUFAs. Data support that CB1 
receptors in the periphery play a role in modulating inflammation related to autoimmune 
diseases.66 Omega-3 LCPUFA-derived ethanolamides, DHEA and EPEA, have been shown to 
inhibit the proliferation of cancer cells.68 Endocannabinoids also play a role in fertility and 
reproduction for both males and females. Anandamide has been identified to be present in sperm, 
and it is believed to play a role in sperm motility and fertilization.57 On the other hand, in 
females AEA has been shown to play a role in blastocyst implantation, embryonic survival, and 
placental development.65,67  
Table 2.3. Physiological Roles of Members of the Endocannabinoid Metabolome 
Metabolite Physiological role Reference 
AEA Reproduction 
Stimulates food intake 
Mediator of metabolic homeostasis 
Cognitive performance 
 
Pagotto, et al., 200655 
Iannotti et al., 201669 
 




Pagotto, et al., 200655 





Reduces enzymatic breakdown of 
AEA 
 
Williams et al., 200760 
Witkamp, 201666 
Iannotti et al., 201669 
OEA Inhibits EC catabolism  
Reduces AEA cellular uptake and 
degradation 
Regulates food intake 
Neuroprotective 
 
Williams et al., 200760 
Taylor et al., 201067 
Iannotti et al., 201669 
(table cont’d.)   
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Metabolite Physiological role Reference 
PG 
 
Increases 2-AG affinity to CB2 Williams et al., 200760 
DHEA  Anti-inflammatory 
Inhibits proliferation of prostate and 
breast cancer cells 
Witkamp, 201666 
Brown et al., 201068 
Brown et al., 201171 
 
EPEA Inhibits proliferation of prostate and 
breast cancer cells 
 
Brown et al., 201068 
EEA, OG, DHG, EPG, EG 
 
Remains to be elucidated 
 
 
ECM and its interaction 
with the ECS 
Feeding regulation 
Energy expenditure  
Reward mechanisms 
Regulation of metabolic homeostasis 
Regulation of pain and inflammation 
Modulation of immune function 
 
CB1localization in the body: 
Brain, adipose tissue, pancreas, 
gastrointestinal tract, skeletal 
muscle, heart, liver, lungs, bone, 
skin, and reproductive system 
 
CB2 localization in the body: 
Immune system (cells such as 
monocytes, macrophages, and B- 
and T-cells) 
Iannotti et al., 201669 
Silvestri et al., 201372 
Mouslechet et al., 200973 
 
Anandamide (AEA), arachidonoyl glycerol (2-AG), palmitoyl ethanolamide (PEA), oleoyl 
ethanolamide (OEA), palmitoyl glycerol (PG), docosahexaenoyl ethanolamide (DHEA), 
eicosapentaenoyl ethanolamide (EPEA), eicosenoyl ethanolamide (EEA), oleoyl glycerol 
(OG), docosahexaenoyl glycerol (DHG), eicosapenaenoyl glycerol (EPG), eicosenoyl 
glycerol (EG), endocannabinoid metabolome (ECM), endocannabinoid system (ECS), 
cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2) 
 The ECS also modulates motility, inflammation, and secretion in the gastrointestinal 
tract.55 Lipid and glucose metabolism are controlled by EC activity, predominantly in the liver 
and adipose tissue.72 Blockade of CB1 has been shown to exert anti-obesity effects64; thus, CB1 
activation by AEA or 2-AG stimulates food intake.55 Researchers have determined in rodent 
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models that 2-AG concentrations increase during fasting and return to normal values when 
animals are being fed to satiation.74     
 Taken together, EC appear to have roles in maintaining homeostasis. The ECS and ECM 
offer a promising opportunity for treating and modulating physiological and pathological 
conditions. Despite a wealth of research conducted to date, many roles and mechanisms remain 
to be elucidated. Animal and clinical research is still needed in order to support any possible 
therapeutic roles of the ECS.  
Endocannabinoid Concentrations are affected by Dietary Fatty Acids 
Concentrations of the EC respond to dietary intake of LCPUFAs, recalling that these fatty 
acids are precursors for EC synthesis. Wood et al. (2010)75 evaluated the impact of a two-week 
dietary DHA supplementation on the ECM in murine brain and plasma. The DHA-enriched diet 
elevated concentrations of n-3 LCPUFAs, DHA and EPA, and their respective derived ECs, 
DHEA and EPG, in both brain and plasma. Work by Artmann et al. (2008)76 showed in a rat 
model that short term consumption of diets resembling human diets specifically modulated tissue 
levels (brain, liver, and small intestine) of EC. Similarly, Matias et al. (2008)77 demonstrated that 
n-3 PUFAs produced a decrease in AEA and 2-AG concentrations while n-6 ARA produced an 
increase in isolated mouse adipocytes, pointing to dietary PUFAs as modulators of EC 
concentrations in adipocytes. Berger et al. (2001)78 demonstrated that AEA, DHEA, and EPEA 
concentrations in piglets’ brain were increased by ARA and DHA in the feed. In another study 
by Watanabe and Hamazaki (2003),79 with mice fed an n-3 PUFA deficient or enriched diet, it 





2.3 Role of Endocannabinoids during Lactation 
Members of the ECM have been recently identified in human milk.80-82 Seminal work by 
Dr. Esther Fride in the 2000s supported a proposed role of the ECS during lactation.83 In 2001, 
Fride and colleagues,83 after evaluating the effect of a CB1 antagonist administrated to newly 
born mouse pups, concluded that the ECS plays a vital role in the suckling response. Mouse pups 
were injected with a CB1 antagonist (SR141716A) at either day one or two only or from day two 
through day eight after birth. As a result, pups stopped suckling after CB1 antagonist 
administration which resulted in growth inhibition after the first injection and death by day eight. 
Observations were confirmed when the antagonist effect was minimized by co-administration of 
Δ9-THC or 2-AG and entourage mediators, PG and linoleoyl glycerol, which delayed pup 
mortality rates. This CB1 antagonist effect suggested that CB1 and 2-AG activity is needed for 
growth and survival. A similar study was conducted using a different strain of mice,84 confirming 
that CB1 antagonist administration reduced milk intake and survival rates. It was concluded that 
CB1 receptor-binding activity played a critical role in initiating the suckling response in the 
newborn mice. Experiments were then undertaken to analyze potential physiological/behavioral 
mediators by which CB1 antagonist inhibit milk ingestion.85 Mouse pups that were administered 
the CB1 antagonist, when manually brought in proximity to the mother’s nipple, failed to hold 
on to the nipple although they opened their mouths and made suckling movements. These data 
suggested that the CB1 receptor influences the oral-musculature needed to latch on. Taken 
together, Fride’s work83-85 proposed that 2-AG, which binds to CB1, levels in the pup’s brain 
stimulates the suckling response at birth. Then, 2-AG from maternal milk activates the CB1 
receptor in the pup’s brain to continually stimulate suckling. When CB1 in the pup’s brain was 
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blocked by an antagonist, pups did not ingest milk which resulted in maternal 2-AG deficit in the 
pup’s brain to activate the CB1 receptor to stimulate milk suckling.  
Cannabinoid receptor type 1 is present in brain areas that are related to motor control, 
emotional responses, motivated behavior, and energy homeostasis.73 Thus, the role of the ECS in 
establishing the oral-musculature behavior needed for milk suckling can be understood. In 
addition, provided that the ECS plays a role in regulating food intake, 2-AG is needed to 
facilitate infant latching onto the breast and nursing. Although data at this moment are scarce, it 
is of great interest to evaluate how the ECS may affect infant nursing behavior to ensure that 
milk is provided to deliver the infant with the countless benefits of breastfeeding, especially 
growth and development during the first months of life. 
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CHAPTER 3  
ENDOCANNABINOID METABOLOME OF BREAST MILK: A COHORT 
FROM GUATEMALA 
3.1 Introduction 
Under conditions of good nutritional health for the mother, breast milk has been 
recognized as the ideal food for meeting growth and development of the infant. The lipids of 
breast milk include the essential fatty acids, α-linolenic acid (ALA, 18:2n3) and linoleic acid 
(LA, 18:2n6), and the long-chain polyunsaturated fatty acids (LCPUFAs), arachidonic acid 
(ARA, 20:4n6) and docosahexaenoic acid (DHA, 22:6n3).1 Docosahexaenoic acid and ARA are 
the most abundant LCPUFAs in fetal brain as they are used for structure and function; both 
accumulate in the infant’s brain from gestation continuing after birth.2 Worldwide, 
concentrations in human milk are 0.47% for ARA and 0.32% for DHA, estimated as a weight 
percentage of total fatty acids. Arachidonic acid is important for growth, whereas DHA plays a 
key role in visual and cognitive development of the infant.3-9  
The LCPUFAs have been characterized as precursors of metabolic mediators that include 
endocannabinoids (EC).10,11 Endocannabinoids are present in the body with a high presence of 
cannabinoid receptor type 1 (CB1) in the central nervous system and cannabinoid receptor type 2 
(CB2) in the periphery.12 Cannabinoid receptor type 1 is present in brain areas that are related to 
motor control, emotional responses, motivated behavior, and energy homeostasis.13 The 
endocannabinoid system (ECS), comprised of EC, receptors, and enzymes,14 has been shown to 
modulate physiologic responses in the human body.15 The endocannabinoid metabolome (ECM) 
has been described as a set of metabolites that include EC and EC-like compounds that interact 
with the ECS to exert metabolic responses.16,17 For the purpose of the present study, the ECM 
includes i) members of the ethanolamide derivatives: anandamide (AEA), palmitoyl 
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ethanolamide (PEA), oleoyl ethanolamide (OEA), docosahexaenoyl ethanolamide (DHEA), 
eicosapentaenoyl ethanolamide (EPEA), and eicosenoyl ethanolamide (EEA); ii) members of the 
glycerol derivatives: arachidonoyl glycerol (AG), palmitoyl glycerol (PG), oleoyl glycerol (OG), 
docosahexaenoyl glycerol (DHG), eicosapenaenoyl glycerol (EPG), eicosenoyl glycerol (EG); 
and iii) precursor LCPUFAs: ARA, DHA, and eicosapentaenoic acid (EPA, 20:5n3). 
Endocannabinoid metabolites, particularly AG which is derived from ARA and binds to 
CB1 with high affinity, have been demonstrated to play a role in establishing the suckling 
response in the newborn by activating the oral-motor musculature needed for milk suckling and 
therefore infant feeding.18-20 Research conducted by Fride et al. (2001)18 in animals demonstrated 
that when a CB1 antagonist (SR141716A) was administered to mouse pups either at day one or 
two only, or from day two to eight after birth, growth inhibition and death occurred by day eight 
after mice stopped suckling following the CB1 antagonist administration. Fride (2004)19 also 
demonstrated that when mice were administered a CB1 antagonist and were brought into 
proximity to the mother’s nipple, even though mice opened their mouths and made suckling 
movements, they failed to hold on to the nipple; thus, suggesting that CB1 binding activity 
influenced the oral-musculature needed to latch on.  
Guatemala is located in Central America and it is categorized by the World Bank as a 
lower middle income country with 59.3% of its population living in poverty.21 Prevalence of 
underweight in children less than five years of age is 12.6%,21 and based on the Ministry of 
Public Health and Social Assistance of Guatemala (2017),22 46.5% of these children are stunted 
(low height for age), making it the seventh highest rate of stunting in the world.23 Guatemala’s 
indigenous population, comprising 41% of its total population,24 suffer higher disparities in 
nutrition compared to mestizos/ladinos, with its children and women especially affected.25 For 
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these children, breastfeeding represents the most effective deterrent for disease prevention and 
nutrient insufficiency. For the entire Guatemalan population, the exclusive breastfeeding rate for 
infants under six months of age is 53% and 57% of two year old children continue breastfeeding 
in addition to consuming foods.23 It is well established that undernourished children may be at 
higher risk of growth retardation, health issues, and impaired cognitive development.26 These 
data underscore the importance of breast milk for meeting the nutritional needs of Guatemala’s 
children and especially the children of the indigenous population.  
Research by our group has recently identified the ECM in human breast milk from a 
population within the United States.27-29 The present study aimed to characterize and quantify the 
ECM in human milk samples from an underserved population in Guatemala. 
3.2 Materials and Methods 
Study Design 
 This was an exploratory-longitudinal study with breast milk samples collected between 
16 to 24 weeks (4 to 6 months) postpartum from lactating women living in the western highlands 
of Quetzaltenango, Guatemala. This was an ancillary study from the ‘Short term response of 
breast milk micronutrient concentrations to a lipid based nutrient supplement in Guatemalan 
women’ parent study which was approved by the Institutional Review Boards at the University 
of California, Davis and the Center for the Studies of Sensory Impairment, Aging and 
Metabolism (CeSSIAM) in Guatemala. For the purpose of this study, only the details pertaining 
to the breast milk samples collected for analysis of the ECM are presented. 
Subject Recruitment 
 Recruitment of subjects was conducted at the community health center and rural 
communities in the geographical area of Quetzaltenango, Guatemala. Quetzaltenango is the 
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second largest city in the country and is 125.5 miles away from the capital, Guatemala City. It is 
located in the western highlands, surrounded by mountains and volcanos. The indigenous 
population predominates in this area comprising 60.3% of Quetzaltenango’s total population.30  
Lactating women between 16 to 24 weeks postpartum were invited to participate by 
asking them in person while potential participants were in the waiting room in the community 
health center or by distributing a flier with information about the study. Women who 
demonstrated interest in participation in the study were screened for inclusion based on the 
following criteria:  
 Mother 18-40 years of age 
 Apparently healthy (determined by anthropometrics), with no acute illness (for example 
flu, diarrhea or mastitis) 
 Breastfeeding at 16-24 weeks (4-6 months) 
 Willing to stay at the clinic for breast milk sampling  
 4-6 months of lactation and ≥ 8 breast feeding episodes per day (usual frequency >20 
times/day) 
 Last birth was a singleton birth 
 Only breastfeeding one child 
 Child was 4-6 months of age 
Women were contacted to schedule (i) the consent process (for thorough explanation of the study 
and for signature of the consent form) and (ii) study visits to the clinic. 
Sample collections 
 Participants were instructed to go to the clinic on four days approximately one week 
apart, each day representing a study visit. During the first visit, participants provided 
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demographic data and anthropometric measures were taken. At 16-24 weeks postpartum (visits 
two, three, and four), fasting mothers were scheduled for breast milk collections between 6 and 7 
am. Women were encouraged to feed the infant from one breast while the researcher collected a 
sample from the opposite breast. Milk collections were made with a manual breast pump 
(Medela, McHenry, IL) by using the mid-feed sampling method in which the mother was 
instructed to feed her infant for one minute before the milk sample was collected. Following a 
one-minute collection, the mother continued feeding the infant.31 Samples were immediately 
aliquoted in 2 mL tubes and stored in a cooling container with ice packs, transferred to a -20 °C 
freezer within 2 hours, then transferred to a -80 °C freezer within 2 weeks. Samples were shipped 
from Guatemala to the Western Human Nutrition Research Center in Davis, CA on dry ice where 
samples were stored at -80 °C. Then, samples were shipped overnight on dry ice to the Center for 
Drug Discovery at Northeastern University, Boston, MA and kept at -80 °C until analysis. 
Sample analysis 
Breast milk samples were analyzed by liquid chromatography-mass spectrometry (LC-
MS) with a state of the art methodology established at the Center for Drug Discovery at 
Northeastern University, Boston, MA. Milk samples were thawed in a 37 °C water bath and 
vortexed at medium speed for 10 s at room temperature. Protein precipitation was carried out 
with chilled acetonitrile and PBS (pH 7.4) and the addition of an internal standard mixture, 
followed by centrifugation (14,000 × g, 5 min, 4°C). The resulting supernatant was diluted with 
four volumes of 5% phosphoric acid followed by solid phase extraction using OASIS HLB 
reverse-phase chromatography cartridges (Waters Corp., Mildford, MA) which were previously 
rinsed with methanol and water prior to loading the diluted samples. Loaded cartridges were 
washed with 40% aqueous methanol prior to eluting the absorbed lipids with acetonitrile. The 
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acetonitrile fraction was evaporated to dryness under nitrogen, reconstituted in ethanol, vortexed 
and sonicated, and centrifuged prior to LC-MS analysis. The autosampler was kept at 4 °C to 
prevent analyte degradation. A TSQ Quantum Ultra triple quadrupole mass spectrometer 
(Thermo Electron, San Jose, CA) with an Agilent 1100 liquid chromatograph (Agilent 
Technologies, Wilmington, DE) at the front end was used for identification and quantification. 
Separation of analytes was carried out using an Agilent 2.1x50 mm, 5 μm Zorbax SB-CN 
column16,32 with gradient elution using 10 mM ammonium acetate (pH 7.3) and methanol (flow 
rate, 0.5 ml/min). Elution of fatty acids was achieved while the mass spectrometer was in 
negative ionization mode, followed by a change in the mass spectrometer to positive ionization 
mode for elution of ethanolamine and glycerol esters. Eluted peaks were ionized via atmospheric 
pressure chemical ionization in multiple reaction monitoring mode. Deuterated internal standards 
were used to derive a standard curve for each analyte and concentrations (ng/mL) of breast milk 
were calculated. Each sample was analyzed in triplicate and concentrations were averaged.   
Statistical analyses 
Statistical analyses were performed using SAS by SAS Institute, Inc., version 9.4 (Cary, 
NC). The level of significance was set at ≤ 0.05. Descriptive statistics (mean, standard deviation, 
and range) were used for numeric variables. Repeated measures analysis of variance using proc 
mixed was used to assed the effect of time on the concentrations of members of the ECM. The 
relationship between the parent fatty acid and its respective derived EC was assessed by 
calculating Pearson correlation coefficients. 
3.3 Results 
 Twenty-six maternal-infant dyads were recruited to participate in this study. Table 3.1 
shows participant characteristics. On average, mothers had a body mass index of 26.3 ± 4.2 
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kg/m2 and a mid-upper-arm circumference of 28.0 ± 3.1 cm. Infants were 4.5 ± 0.5 months old, 
weighed 7.0 ± 1.1 lbs., and the majority (65%, n = 17) had a normal height to length ratio. 
    Table 3.1. Maternal-Infant Characteristics (n = 26) 
Characteristics Mean or % (frequency) SD 
Maternal BMI (kg/m2) 26.3 4.2 
Maternal MUAC (cm) 28.0 3.1 
Maternal literacy (literate) 88.5 (23)  
Marital status (married)  100 (26)  
Infant age at start (months) 4.5 0.5 











Severely stunted  
-1.33 




BMI, body mass index; MUAC, mid-upper-arm circumference; HAZ, 
length-for-age Z-score 
Table 3.2 shows the average concentration of the members in the ECM. Standard curves 
for each member were linear and had regression values ≥ 0.99. Overall, ECM concentrations in 
the glycerols were between 2,000 to 4,850 times higher than the concentrations for the 
ethanolamides. For some ECM members, the range was highly variable. Arachidonic acid was 
the principal LCPUFA with 70.8%, followed by DHA and EPA with 21.8% and 7.4%, 
respectively.  Palmitoyl ethanolamide was the main metabolite in the ethanolamide group 
comprising 90.6%, followed by OEA with 7.7%, and AEA, DHEA, EPEA, and EEA comprising 
the remaining 1.7%. For the glycerol group, PG comprised 84.5%, OG 13.9%, and AG, DHG, 
EPG, and EG the remaining 1.6%. The samples did not contain the full aliquot needed to detect 
ethanolamides and EPG with confidence. EPEA was not detected in most of the samples. For 
some samples, PEA and PG were above the standard curve. However, these values were close to 
the curve and it could be assumed that they did not saturate the detector. Therefore, those results 
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should be interpreted with caution and used more as a guide than as a reference in comparisons 
to other data/results.  
There was a time effect across the three collection days of sampling for the 
concentrations of PEA and the LCPUFAs ARA, DHA, and EPA (p ≤ 0.05) (Table 3.2). 
Concentrations were higher on the third day of collection for PEA and on the second day for 
ARA, DHA, and EPA. There was a significant correlation between the parent fatty acid and its 
derived EC in the glycerol group for ARA and AG (r = 0.66, p ≤ 0.01) and DHA and DHG (r = 
0.90, p ≤ 0.01) (Figure 3.1). Arachidonic acid and DHA concentrations did not correlate with 
AEA and DHEA, respectively. A small correlation was found for AEA and AG (r = 0.32, p ≤ 
0.01). For EPA, there were no correlations for its derived EC, EPEA or EPG. 
Table 3.2. Endocannabinoid Metabolome of Breast Milk 
Metabolite 
Mean ± SD 
ng/mL 






1672.87 ± 1119.42 
514.13 ± 404.02 
173.50 ± 216.19 
 
176.69 – 6187.31 
  41.38 – 2549.15 













0.05 ± 0.03 
12.39 ± 26.15 
1.06 ± 0.81 
0.07 ± 0.07 
0.08 ± 0.16 
0.02 ± 0.01 
 
       0.01 – 0.14 
 0.27 – 143.43 
       0.14 – 4.80 
       0.03 – 0.48 
      -0.03 – 0.56 
















       135.00 ± 95.51 
26730.13 ± 18583.17 
4395.75 ± 3088.07 
259.05 ± 221.31 
14.02 ± 13.14 
97.00 ± 68.35 
 
  6.45 – 472.71 
2189.00 – 95047.28 
  418.69 – 14720.33 
  17.56 – 1350.77 
0.68 – 74.38 








1p value represents the effect of time across the three time points. Significant difference marked in bold. 2Some values were 
below the standard curve. 3Some values were above the standard curve. NA, not analyzed (not enough values to calculate). 
ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AEA, Anandamide; PEA, palmitoyl 
ethanolamide; OEA, oleoyl ethanolamide; DHEA, docosahexaenoyl ethanolamide; EPEA, eicosapentaenoyl ethanolamide; 
EEA, eicosenoyl ethanolamide; AG, arachidonoyl glycerol; PG, palmitoyl glycerol; OG, oleoyl glycerol; DHG, 





Figure 3.1. Correlations between the precursor fatty acid and 
its derived endocannabinoid. Figure at the top shows the 
correlation between arachidonic acid (ARA) and anandamide 
(AEA). Figure at the bottom shows the correlation between 
docosahexaenoic acid (DHA) and docosahexaenoyl glycerol 
(DHG).  
3.4 Discussion 
 Our study provides the first report for the ECM in human breast milk from a developing 
country. Other studies have reported on members of the ECM, mainly AEA and other 
ethanolamides, in human breast milk but these studies have focused on populations from the 
United States,27,29,33 Sweden,34 Israel,18 or the United Kingdom.35 As Guatemala has the seventh 
highest rate of stunting in the world,25 breast milk, the ‘liquid gold’, becomes a very important 
source of nutrients for infants and children and provides a means for addressing infant 










































Correlation between DHA and DHG
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determined that 58% of women were either exclusively or predominantly breastfeeding their 
infants at six months of life. 
 In the current study, we evaluated the presence of ECM members in mature (16-24 
weeks) milk to characterize the metabolites present in breast milk and to quantify them. Our 
results for AEA, EEA, and PG are very similar to those presented by Lammi-Keefe et al. 
(2017)27 for breast milk at 10 weeks postpartum from a cohort in Baton Rouge, Louisiana; 
however they differ for the rest of the ECM members. For both populations, Lammi-Keefe et al. 
and the present study, PEA, PG, and ARA were the main metabolites in the ethanolamide, 
glycerol, and fatty acid groups, respectively. In the current study, AG was present in higher 
concentrations in breast milk than that for AEA (2,700 times higher), which is similar to the 
finding of Fride et al. (2001)18 who reported that AG was 5,800 times higher than AEA in mature 
milk. This finding may support the importance of AG for establishing the suckling response in 
the newborn18,20,37,38 as breast milk will be a continuous exogenous source of AG for the infant’s 
brain. In the current study, glycerol metabolites tended to be present in higher concentrations 
than ethanolamides as previously reported by Fride et al. (2001)18 and Lammi-Keefe et al. 
(2017)27 for breast milk. Although both AG and AEA and also DHG and DHEA are derived 
from ARA and DHA, respectively, synthesis/degradation rates may differ between those two 
groups presumably by the action of enzymes such as fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase.39 Affinities of anabolic and catabolic enzymes for the EC likely differ 
for each metabolite. For example, FAAH is the principal enzyme for metabolizing AEA although 
it can also act on AG albeit at a different rate.40 In addition, the presence of entourage 
metabolites41 (e.g. PG, OG, OEA, DHG, EPEA, etc.) can interfere with enzyme activity as some 
of these metabolites can act as substrate for the same enzymes. Alternatively, metabolites may 
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inhibit uptake and degradation of EC or increase receptor affinity for either CB1 or CB2.16 Any 
of these factors would presumably impact the activity of one over another. Entourage 
metabolites41 (PEA, OEA, DHEA, EPEA, EEA, PG, OG, DHG, EPG, and EG) in breast milk of 
our population could support AG’s function. At this time there is insufficient evidence to 
speculate about the synthesis and degradation pathways for each group of metabolites, 
ethanolamides versus glycerols. A limited number of studies have reported EC concentrations in 
human breast milk, all with different study limitations including a limited number of study 
subjects to variation in lactation stage when samples were collected. Nonetheless, all of these 
studies18,27,29,33-35 support the presence of different EC and EC-like components in breast milk.      
In a global survey of the n-3 fatty acids EPA and DHA conducted by Stark et al. (2016),42 
it was determined that Guatemala had a relative low n-3 status (< 4% DHA+EPA of total fatty 
acids in erythrocytes) compared to other countries worldwide. In a study conducted by Solomons 
et al. (2015)43 in the Pacific Coast area of Guatemala, it was determined that women and children 
had a DHA status of 3.09% and 3.49%, respectively. Additionally, in a study in the geographical 
area of Quetzaltenango, Bermudez et al. (2010)44 reported that children were consuming limited 
amounts of DHA (32 mg/day) and food sources of DHA included eggs, chicken, fish, and 
shrimp. These data provide an overview of the diet in the population included in this study. 
Considering the important role of DHA for pregnancy and development outcomes,45 including 
the roles as a precursor for EC metabolites, there is a need to assess dietary intake of fatty acids. 
In the current study, LCPUFAs ARA, DHA, and EPA were present in breast milk. For a similar 
population in Quetzaltenango, N. Solomons, MD (email communication, April 2018) has 
reported the amounts of DHA+EPA in breast milk to be 0.23% of the total fatty acids, an amount 
lower than the average worldwide of 0.32% for DHA.46 Although dietary data were not available 
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for the current study, it might be speculated that dietary sources contributed to the high range of 
concentrations found for most of the ECM members. As maternal diet is a source for EC 
precursors, i.e. fatty acids, it is of great importance that these women consume enough fatty 
acids, especially the LCPUFAs, to ensure adequate quantities in breast milk to meet infant 
demands. There was a time effect for the three samples collected in the current study for ARA, 
DHA, EPA, and PEA. Breast milk fatty acids are directly affected by diet,47,48 which suggest a 
direct effect of diet on the LCPUFAs and PEA concentrations between collection dates. 
Differences in time for the LCPUFAs but not for most of the EC and EC-like metabolites may be 
explained, at least in part, by binding affinity, degradation, and synthesis rates and how these are 
utilized by the infant. 
There was a positive correlation between ARA and AG and also DHA and DHG in the 
breast milk for this population. These correlations between the parent fatty acid and its derived 
glycerol- but not its derived ethanolamide-metabolites, may be explained by the fact that 
glycerols are present in breast milk at higher concentrations than ethanolamides as shown in our 
results and other reports.18,27,34 In addition to its role in suckling behavior, AG is also involved in 
stimulating food intake. A study by Kirkham et al. (2002)49 shown that AG levels increased in 
areas of the brain related to motivation to eat when fasting, exerting a stimulation to eat. The role 
of DHG remains to be elucidated. It is plausible, however, that DHA derivatives (i.e. DHG and 
DHEA) sustain infant’s cognitive development.   
Long-chain PUFAs play a critical role in infant development and AG has a documented 
role in infant feeding behavior,37 underscoring the interest and importance of  understanding this 
biological system, the ECM in human milk. Breast milk can be influenced by maternal nutrition 
status, thus modulating infant health. For populations with health disparities and economic 
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disadvantages, understanding breast milk and its biological components can provide insight to 
understanding and addressing stunting rates especially during the first months of age which are 
likely to have an impact later in life. Data are limited at this time. The current study opens the 
door to develop research hypotheses in this field to support the ECM relevance in health and as a 
possible intervention for infants with health disparities.     
3.5 Limitations 
The current study had limitations. The study sample was not necessarily representative of 
the Guatemalan population. Participants were recruited from an underserved population in the 
highlands of Quetzaltenango that is documented to have limited access to a diet that meets 
nutrient requirements. Some breast milk samples were collected in the field where a freezer was 
not available. Therefore, these samples had to be stored in a cooling bag with ice packs until 
taken to the clinic to be stored at -20 °C until transferred to a -80 °C freezer for long term 
storage. The aliquot size was less than the amount needed to detect ethanolamides and EPG 
concentrations with confidence; thus ethanolamides, especially EPEA, were not detected as 
originally planned. The data from this study should be interpreted with caution and considered 
preliminary findings that provide one of the first reports on the ECM of human breast milk. 
3.6 Conclusion 
 Our study identified members of the ECM in mature breast milk and provided, to the best 
of our knowledge, the first report for a population with health disparities within a developing 
country. These data indicate that EC and EC-like components may play a role in infants’ feeding 
behaviors which, in turn, influence infant growth and development. Our finding of differences of 
some metabolites over time warrants further investigation with regards to maternal diet. The 
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role(s) of each member in the ECM in infant development have not yet been established and this 
also warrants further investigation. 
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ENDOCANNABINOID METABOLOME OF BREAST MILK: A COHORT 
FROM BATON ROUGE, LOUISIANA 
4.1 Introduction 
According to the Center for Disease Control and Prevention (2016),1 almost 61% of 
infants in Louisiana are ever breastfeed, with 31.2% breastfeeding at six months, 13.3% 
breastfeeding at 12 months, and only 11.8% meeting the global recommendation to breastfeed 
exclusively for six months.2,3 The recommendation for exclusive breastfeeding during the first 
months following delivery is based in part on the knowledge that breast milk provides the infant 
with nutrients that meet his requirements during development. These beneficial nutrients include 
the long-chain polyunsaturated fatty acids (LCPUFAs), docosahexaenoic acid (DHA, 22:6n3) 
and arachidonic acid (ARA, 20:4n6), that play a pivotal role in cognitive and retinal development 
and growth of the infant.4 These nutrients are transferred to the infant across the placenta during 
pregnancy and through breast milk after birth. 
 It has been shown that LCPUFAs are precursors to endocannabinoids (EC) which are 
endogenous lipid mediators that bind to the same receptors as Cannabis sativa (marijuana).5 
Endocannabinoids have been shown to play a pivotal role in appetite and food intake6 by 
activating cannabinoid receptor 1 (CB1) which is predominant in the central nervous system.7 
Cannabinoid receptor 1 is activated by two different EC, arachidonoylethanolamide 
(anandamide, AEA) and arachidonoyl glycerol (2-AG or AG), both derived from n-6 ARA. In 
particular, for infant feeding behavior, 2-AG has been demonstrated to play a role in establishing 
the suckling response of the neonate when nursing.8 Evidence in mouse pups suggest that CB1 
activation by 2-AG is needed to establish the suckling response by activating the oral-motor 
musculature behavior needed for milk suckling.8-10 Establishment of this role for 2-AG was 
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demonstrated after administration of a CB1 antagonist (SR141716A) to mouse pups which 
resulted in growth inhibition and even death by day eight after birth.8 
Recent work has indicated that EC and EC-like compounds (collectively referred to as 
the endocannabinoid metabolome, ECM) are present in human breast milk.11,12 
Endocannabinoid-like compounds, referred to as entourage metabolites,13 may support the 
activity and physiologic responses of the EC system by interacting with AEA and AG, their 
enzymes, or their receptors. These entourage metabolites exert cannabimimetic effects (similar 
pharmacological effects to those of cannabis).14 The ECM encompasses 15 metabolites identified 
to date: i) ethanolamide derivatives: AEA, palmitoyl ethanolamide (PEA), oleoyl ethanolamide 
(OEA), docosahexaenoyl ethanolamide (DHEA), eicosapentaenoyl ethanolamide (EPEA), and 
eicosenoyl ethanolamide (EEA); ii) glycerol derivatives: 2-AG, palmitoyl glycerol (PG), oleoyl 
glycerol (OG), docosahexaenoyl glycerol (DHG), eicosapenaenoyl glycerol (EPG), eicosenoyl 
glycerol (EG); and iii) precursor LCPUFAs: ARA, DHA, and eicosapentaenoic acid (EPA, 
20:5n3). There is limited information regarding the ECM of human breast milk and its role in 
infant development. Thus, in the present study, we characterized and quantified the ECM in 
human breast milk in transitional and mature milk and evaluated if the concentrations of these 
metabolites changed over time.     
4.2 Materials and Methods 
Study Design 
 This research project was an exploratory-longitudinal study to evaluate if there was a 
difference in the ECM of transitional milk (two weeks postpartum) and the ECM of mature milk 





Pregnant women from the greater Baton Rouge, Louisiana area who were planning to 
breastfeed for a minimum of four weeks were invited to participate in this study. Recruitment 
was based on intent to breastfeed. Subjects were invited to participate before delivery through 
private physicians’ offices and hospital prenatal clinics or by posting flyers describing the study 
around the community. Women who demonstrated interest in participation in the study were 
contacted to explain the study and for pre-screening based on the inclusion criteria:  
 Maternal age of 18-40 years at the time of delivery  
 Full term delivery ( ≥ 37 gestational weeks) 
 Singleton birth 
 Plan to breastfeed for at least 4 weeks 
 Willing to provide a breast milk sample (complete breast emptying from one breast) 
during the morning (6-10 am) 
 Have not been breastfeeding or pregnant in the previous year 
Before delivery, women were contacted again to schedule the consent process (thorough 
explanation of the study and for signature of the consent form). The exclusion criteria were 
discussed at the time of consent: 
 Any tobacco use during lactation 
 Alcohol consumption ( >1 drink per week) 
 Presumed or confirmed congenital birth defects 
Materials provided to the subjects for the study included two breast milk storage bags, 
instruction on how to collect the breast milk sample, and a schedule card for visits. These were 
44 
 
provided the same day that the consent was obtained. The Louisiana State University 
Agricultural Center Institutional Review Board approved the study. 
Sample collection 
 Participants provided written consent and filled out a health history questionnaire that 
included questions about previous and current pregnancies, pregravid body mass index (BMI), 
and prior lactation experience. Details regarding infant birth weight and length were completed 
following the infant’s birth. In addition, participants provided information about education and 
socioeconomic status. This information was confirmed by their health care providers.  
Breast milk samples: 
Samples were collected at two and four weeks postpartum at the participants’ homes. 
Participants were asked to provide a breast milk expression from a single breast (emptying a full 
mammary gland by collecting all the milk from that breast)15 by using an electric breast pump. In 
preparation for milk collection, participants fasted for at least two hours and collections were 
made between 6 and 10 am. The sample was stored under refrigeration at the participant’s house 
(for a maximum of 24 hours) in the breast milk storage bag provided by the researcher. Samples 
were transported on ice to the laboratory where the milk was warmed in a 37 °C water bath, 
manually gently swirled to mix, and ~15 mL aliquots were made in small glass vials with 
Teflon-lined caps and stored at -80 °C until analyses. Information including the breast pump 
brand used, exclusive breastfeeding, and use of formula for supplementation were also recorded. 
Samples were shipped overnight on dry ice to the Center for Drug Discovery, Northeastern 






The breast milk samples were analyzed by liquid chromatography-mass spectrometry 
(LC-MS) with a state-of-the-art methodology established at the Center for Drug Discovery at 
Northeastern University, Boston, MA. Milk samples were thawed in a 37 °C water bath and 
vortexed at medium speed for 10 s at room temperature. Protein precipitation was carried out 
with chilled acetonitrile and PBS (pH 7.4) and the addition of an internal standard mixture, 
followed by centrifugation (14,000 × g, 5 min, 4°C). The resulting supernatant was diluted with 
four volumes of 5% phosphoric acid followed by solid phase extraction using OASIS HLB 
reverse-phase chromatography cartridges (Waters Corp., Mildford, MA) which were previously 
rinsed with methanol and water prior to loading the diluted samples. Loaded cartridges were 
washed with 40% aqueous methanol prior to eluting the absorbed lipids with acetonitrile. The 
acetonitrile fraction was evaporated to dryness under nitrogen, reconstituted in ethanol, vortexed 
and sonicated, and centrifuged prior to LC-MS analysis. The autosampler was kept at 4 °C to 
prevent analyte degradation. A TSQ Quantum Ultra triple quadrupole mass spectrometer 
(Thermo Electron, San Jose, CA) with an Agilent 1100 liquid chromatograph (Agilent 
Technologies, Wilmington, DE) at the front end was used for identification and quantification. 
Separation of analytes was carried out using an Agilent 2.1x50 mm, 5 μm Zorbax SB-CN 
column16,17 with gradient elution using 10 mM ammonium acetate (pH 7.3) and methanol (flow 
rate, 0.5 ml/min). Elution of fatty acids was achieved while the mass spectrometer was in 
negative ionization mode, followed by a change in the mass spectrometer to positive ionization 
mode for elution of ethanolamine and glycerol esters. Eluted peaks were ionized via atmospheric 
pressure chemical ionization in multiple reaction monitoring mode. Deuterated internal standards 
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were used to derive a standard curve for each analyte and concentrations (µg/mL) of breast milk 
were calculated. Each sample was analyzed in triplicate and concentrations were averaged.   
Statistical analyses 
Statistical analyses were performed using SAS by SAS Institute, Inc., version 9.4 (Cary, 
NC). The level of significance was set at ≤ 0.05. Descriptive statistics (mean, standard deviation, 
and range) were used for numeric variables. Repeated measures analysis of variance using proc 
mixed was used to assed the effect of time across the two different time points on the 
concentrations of members of the ECM. 
4.3 Results 
One hundred thirty-one potential participants were invited to participate in the study from 
which 31 consented to participate. Seven women dropped out during the study; thus, data from 
24 participants was included in the study. Table 4.1 provides the participants’ characteristics. 
Lactating women in the study were between 18 and 39 years old. Only seven participants (29%) 
indicated having a previous breastfeeding experience. Rates for infants in this study being 
exclusively breastfed were 83% (n = 20) and 67% (n = 16) at two and four weeks, respectively.    
Table 4.2 shows the constituents of the ECM at two weeks (transitional milk) and four 
weeks (mature milk) postpartum. Standard curves for each metabolite were linear and had 
regression values ≥ 0.99, except for PG which was 0.98. Extraction efficiencies were greater than 
80%, except for OG which was greater than 78%. The main metabolite present in the fatty acids 
group was ARA accounting for more than 60% of that fraction. In the ethanolamide group, OEA 
accounted for more than 50% of that portion, and PG in the glycerol group accounted for more 
than 90%. Eicosenoyl ethanolamide and EPG were present in the lowest concentrations in the 
ethanolamide and glycerol groups, respectively.    
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       Table 4.1. Maternal-Infant Characteristics (n = 24) 
Characteristic 
Mean ± SD or  
% (frequency) 
Range 
Maternal Characteristics   
Age (y) 






Gestational age at delivery (weeks) 




Some high school 
High school 
Some college 








30.5 ± 5.0 
28.0 ± 5.8 
 
  71 (17) 
17 (4) 
  8 (2) 
  4 (1) 
39.2 ± 1.3 
 
29 (7) 
  71 (17) 
 
  4 (1) 
  4 (1) 
21 (5) 
25 (6) 
  46 (11) 
 
21 (5) 
  79 (19) 
 
13 (3) 
  88 (21) 
18.0 – 39.0 






37.0 – 41.0 




Mode of delivery 
Vaginal 
Cesarean 
Birth weight (lbs) 
Feeding type 
Exclusively breastfed 
Supplemented with formula 
 
33 (8) 
  67 (16) 
 
  75 (18) 
25 (6) 
  7.4 ± 0.8 
2 weeks 








5.5 – 9.2 
4 weeks 
 67 (16) 
33 (8) 
BMI, body mass index; WIC, Woman, Infant, and Children Special Supplemental 
Nutrition Program 
 For some samples, EPEA and EEA were below the standard curve and PG was above 
although values were close to the curve for the later. Therefore, those results should be 
interpreted with caution. Only DHEA demonstrated a time effect (p ≤ 0.05) across the two 
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different time points postpartum [transitional (two weeks) versus mature (four weeks) milk] with 
higher concentrations in transitional milk. Overall, breast milk glycerol group concentrations 
were higher than those of the ethanolamides. Glycerol concentrations were 15,564 and 56,052 
times higher in transitional and mature milk, respectively than the ethanolamide concentrations.  
    Table 4.2. Endocannabinoid Metabolome of Human Breast Milk 






2818.96 ± 2785.29 
2031.17 ± 2332.63 
381.49 ± 646.23 
 
  7030.33 ± 16674.49 
2384.71 ± 5224.73 













0.15 ± 0.23 
0.90 ± 0.48 
1.48 ± 1.18 
0.11 ± 0.07 
0.07 ± 0.14 
0.03 ± 0.03 
 
0.08 ± 0.04 
0.74 ± 0.40 
1.12 ± 0.47 
0.07 ± 0.03 
0.11 ± 0.20 
















166.85 ± 177.85 
37477.67 ± 35745.95 
4059.33 ± 3511.83 
673.50 ± 970.05 
24.70 ± 37.74 
242.48 ± 327.00 
 
312.11 ± 575.36 
110091.70 ± 261103.75 
  7719.96 ± 10885.00 
  866.30 ± 1839.67 
  61.99 ± 138.34 








All data are presented in ng/ml and are mean ± SD. 1Two and four weeks postpartum. 
2p value represents the effect of time across the two time points. Significant difference 
marked in bold. 3Some values were below the standard curve. 4Some values were above 
the standard curve. 
ARA, arachidonic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; AEA, 
Anandamide; PEA, palmitoyl ethanolamide; OEA, oleoyl ethanolamide; DHEA, 
docosahexaenoyl ethanolamide; EPEA, eicosapentaenoyl ethanolamide; EEA, 
eicosenoyl ethanolamide; AG, arachidonoyl glycerol; PG, palmitoyl glycerol; OG, oleoyl 
glycerol; DHG, docosahexaenoyl glycerol; EPG, eicosapenaenoyl glycerol; EG, 
eicosenoyl glycerol. 
 Combining the two time points together to evaluate relationships, it was observed that 
there were significant correlations between the precursor LCPUFA and its derived EC for ARA 
and AG (r = 0.88, p ≤ 0.01), DHA and DHEA (r = 0.69, p ≤ 0.01), DHA and DHG (r = 0.95, p ≤ 
0.01), EPA and EPEA (r = 0.80, p ≤ 0.01), and EPA and EPG (r = 0.91, p ≤ 0.01). No 
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correlations were observed between ARA and AEA. Docosahexaenoyl ethanolamide correlated 
with DHG (r = 0.61, p ≤ 0.01) and EPEA with EPG (r = 0.84, p ≤ 0.01). 
4.4 Discussion 
To the best of our knowledge, this study is the first to characterize the ECM in 
transitional and mature human milk and to explore differences in the ECM concentrations at 
these two stages of breast milk production. The mechanisms of action and the roles of the ECM 
in both breast milk and for infant development are not fully described/understood. Understanding 
breast milk and its bioactive components (i.e. ECM) provides an opportunity to underline the 
importance of breast milk for infant nourishment and development.  
In this exploratory study, we have characterized the ECM of transitional and mature milk. 
Our results showed that only DHEA, a derivative of n-3 DHA conjugated with ethanolamine, 
was different across the two different time points (p ≤ 0.05) with higher concentrations in 
transitional milk. Research evaluating the role of the endocannabinoid system (ECS) in infant 
feeding behavior has been focused on the activation of CB1 when binding to AG, which in turn 
activates the oral-motor musculature needed for milk suckling.8 However, DHEA has also been 
shown to be an agonist to CB1.18 Although the role of DHEA in food intake has not been 
studied, it may be hypothesized that by binding to the same receptor as AG, DHEA exerts some 
of the same activities. In addition, as DHA plays a key role in infant cognitive development19,20 
and is a precursor to DHEA, it is plausible that DHEA also supports brain development. 
Moreover, the development of the hippocampus, a brain area related to learning and memory, 
has been shown to be supported by DHEA.21 Although the fatty acids and glycerol-derivatives 
were higher and the ethanolamide-derivatives were lower in mature milk, there were no 
significant differences for the other members of the ECM across transitional and mature milk.  
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Perhaps the analysis of colostrum may indicate different results. Colostrum is present for 
the first three to five days after birth22 and its main function is to provide immunological 
protection to the newborn.23 We hypothesize that concentrations of the ECM would be higher in 
colostrum than in mature milk attributable to a higher demand when a newborn is adapting to 
feed at the breast. As a result, ECM concentrations would be higher at the beginning of postnatal 
life and would decrease over time when the infant has established the feeding behavior needed 
for milk suckling. 
Scarce data are available for a comparison with our current results. However, the earliest 
study by Fride et al. (2001)8 that established a role for the ECS in mouse pup suckling and 
growth, also analyzed milk from various sources including human milk. Even though the study 
by Fride et al. (2001) did not specify the number of milk samples analyzed, our results follow the 
same pattern in demonstrating that PG is present in human breast milk in higher concentrations 
than AG. Furthermore, a study by Di Marzo et al. (1998)24 reported 330 ng/ml of AG in mature 
human breast milk, a concentration very similar to our result of 312.11 ng/ml, and indicated that 
AG is found in human breast milk in higher concentrations than AEA which is also demonstrated 
in our present results. Similarly, a study by Schuel et al. (2002)25 in which ethanolamides were 
analyzed in human fluids, including mature milk, demonstrated that OEA was present in higher 
concentrations than PEA, and PEA in higher concentrations than AEA, as also shown in our 
results. In addition, our results are in line with those presented by Lammi-Keefe et al. (2017)11 
who studied a population similar to the current population and analyzed the same members of the 
ECM that were investigated in the current study. Our results follow the same pattern as Lammi-
Keefe et al. (2017) in terms of the proportion of each member within each group: fatty acids, 
ethanolamides, and glycerols. In summary, to the best of our knowledge, there are only a few 
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studies available for a comparison to the findings of our current study that support the presence 
of EC and EC-like metabolites in human breast milk. 
In the current study, we have taken a step to evaluate correlations between the precursor 
LCPUFAs and their ethanolamide- and glycerol-derivatives. There were significant correlations 
(p ≤ 0.01) for DHA-DHEA-DHG, EPA-EPEA-EPG, and ARA-AG but not AEA. The most 
robust correlations were for the precursor LCPUFA and its derived glycerol metabolites: ARA-
AG (r = 0.88), DHA-DHG (r = 0.95), and EPA-EPG (r = 0.91). The strong correlations between 
the precursor LCPUFA with its glycerol- but not its ethanolamide-derivatives, may support a 
more important role for the glycerols (AG, PG, OG, DHG, EPG, and EG) in establishing the 
suckling response of the newborn by modulating motor development and behavior. In addition, 
the presence of entourage metabolites (PEA, OEA, DHEA, EPEA, EEA, PG, OG, DHG, EPG, 
and EG), which exhibit cannabimimetic responses,13 may enhance the activity of the two most 
thoroughly studied EC, AG and AEA. For example, PG has been shown to increase AG affinity 
to CB2 by acting as a lipid signaling mediator17; and PEA and OEA reduce enzymatic 
breakdown, cellular uptake, and degradation of AEA. These entourage metabolites may interfere 
with enzymatic activity as they can also act as substrates for catabolic and anabolic enzymes. In 
addition, the presence of these lipid mediators may prevent EC activation or deactivation. All of 
these interactions may also explain our finding that n-3 LCPUFA derivatives, both 
ethanolamides and glycerols, correlated with each other [DHEA-DHG (r = 0.61, p ≤ 0.01) and 
EPEA-EPG (r = 0.84, p ≤ 0.01)]. The associations among the n-3 LCPUFA derivatives, but not 
for the n-6 derivatives (AEA and AG), leads to the speculation that they support the role of DHA 
in infant cognitive development, although their roles have yet been fully elucidated. 
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To date the mechanisms of action regarding how the ECM as a whole interacts with the 
ECS and its role in infant feeding behavior, and therefore infant development and growth, are 
still poorly understood. Our results provide evidence that there are metabolites similar to the 
previously described EC,5 i.e. AEA and AG, present in human breast milk. With an 
understanding of the role of the ECM and its interactions with the ECS in human breast milk and 
the infants’ brain, potential interventions could be developed for infants with difficulties latching 
on and for preterm infants who could be aided by the countless benefits of breast milk to ensure 
continued development outside the womb. While this is out of the scope of this study, it merits 
further exploration.   
4.5 Limitations 
This study was limited by its small sample size (n = 24). Having a relatively small group 
of participants did not allow for further explorations between the concentrations for some of the 
ECM members and demographic data such as BMI and race, for example. However, this study 
provides an opportunity to develop hypotheses for future studies to evaluate how the ECM of 
breast milk may be modulated on the basis of maternal and/or infant factors. 
4.6 Conclusion 
Our study provides evidence that EC and EC-like metabolites are present in human milk. The 
findings in this study not only support the role of AG in establishing the suckling response of the 
newborn by activating oral-motor musculature needed for milk suckling, but also suggest that 
other bioactive constituents in breast milk may also play a role in infant health and development. 
In addition, knowing that EC-like metabolites are present in breast milk, future studies can be 
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MATERNAL DIETARY FATTY ACIDS AND THEIR RELATIONSHIP TO 
DERIVED ENDOCANNABINOIDS IN BREAST MILK 
5.1 Introduction 
Breast milk provides the infant with nutrients needed for development, beginning 
immediately after birth and continuing into infancy. With respect to these nutrients, of high 
importance are the long-chain polyunsaturated fatty acids (LCPUFAs), docosahexaenoic acid 
(DHA, 22:6n3) and arachidonic acid (ARA, 20:4n6), which play a pivotal role in infants’ 
cognitive and retinal development and growth.1,2 It is established that maternal diet influences 
breast milk composition, especially for the LCPUFA concentrations.3,4 Furthermore, the lipid 
fraction is the most variable nutrient during lactation.5 Within a feed, the fat content is higher in 
the hind milk as to compared to the fore milk.6 During the stages of lactation, the fat content 
varies from 2% in colostrum, 2.9% in transitional milk, and 3.6% in mature milk.7 Worldwide, 
the DHA content of breast milk is reported to be 0.32% and 0.47% for ARA of the total fatty 
acids.8 
During the first six months of lactation, it is recommended that women increase their 
energy intake by 500 kcal/day and by 400 kcal/day from months six through 12.9 Further, 
lactating women are advised more recently to consume at least 200 mg/day of DHA.10 In 
addition, to help meet the requirement for DHA, the Dietary Guidelines for Americans suggest 
that lactating women consume at least 8 and up to 12 ounces of a variety of seafood low in 
methyl mercury per week which provide an average of 250 mg/day of eicosapentaenoic acid 
(EPA, 20:5n3) and DHA combined.11  
Endocannabinoids (EC) are lipid mediators derived from the LCPUFAs.12 The chemical 
structure of EC resembles that of the precursor fatty acid conjugated with either ethanolamine or 
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glycerol.12 Seminal work by Fride et al. (2001)13 identified the presence of the main EC, 
arachidonylethanolamide (AEA) and arachidonoylglycerol (AG) that are both derived from n-6 
ARA, in breast milk from different species including human milk. Very recently, in addition to 
AEA and AG, EC-like metabolites have been identified in human breast milk.14,15 These EC-like 
metabolites include docosahexaenoyl ethanolamide (DHEA) and docosahexaenoyl glycerol 
(DHG) which are derived from n-3 DHA; and eicosapentaenoyl ethanolamide  (EPEA) and 
eicosapenaenoyl glycerol (EPG) that are derived from n-3 EPA.  
Appetite and food intake have been shown to be influenced by the EC.16 In a study using 
a mouse model, Fride et al. (2001)13 determined that AG is needed to activate the oral-motor 
musculature needed for milk suckling. On the basis of evidence in the mouse model and of 
relevance to infant nutrition, research has shown that EC may influence infant feeding behavior 
and that breast milk is an exogenous source of EC for the infant.13,17 There is evidence that 
circulating and tissue levels of EC metabolites are modulated by dietary intake of precursor fatty 
acids.18-20 Nonetheless, the relationship of maternal LCPUFA intake to EC concentrations in 
breast milk has not been previously explored. Therefore, the aim of the present study was to 
assess maternal intake of LCPUFAs and their relationship to concentrations of derived EC and 
EC-like metabolites in breast milk.  
5.2 Materials and Methods 
Study Design 
 This research project was an exploratory study to assess the relationship between dietary 
LCPUFAs and derived EC in breast milk. Dietary intake was collected at two, three, and four 





Lactating women from the greater Baton Rouge, Louisiana area who were planning to 
breastfeed for a minimum of four weeks were invited to participate in this study. Recruitment 
was based on intent to breastfeed. Subjects were invited to participate before delivery through 
private physicians’ offices and hospital prenatal clinics in the greater Baton Rouge area or by 
posting flyers describing the study around the community. Women who demonstrated interest in 
participation in the study were contacted to explain the study and for pre-screening based on the 
inclusion criteria:  
 Maternal age of 18-40 years at the time of delivery  
 Full term delivery ( ≥ 37 gestational weeks) 
 Singleton birth 
 Plan to breastfeed for at least 4 weeks 
 Willing to provide a breast milk sample (complete breast emptying from one breast) 
during the morning (6-10 am) 
 Have not been breastfeeding or pregnant in the previous year 
Before delivery, women were contacted again to schedule the consent process 
(explanation of the study and signature of the consent form). The exclusion criteria were 
discussed at the time of consent: 
 Any tobacco use during lactation 
 Alcohol consumption ( >1 drink per week) 
 Presumed or confirmed congenital birth defects 
Materials provided to the subjects for the study included two breast milk storage bags, 
instructions on how to collect the breast milk samples, a schedule card for study visits, and food 
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amounts booklet (for calculating portion sizes of foods consumed). These were provided the 
same day that the informed consent process was conducted. The study was approved by the 
Louisiana State University Agricultural Center Institutional Review Board. 
Sample collections 
After providing written consent, participants were asked to fill out a health history 
questionnaire that included questions about previous/current pregnancy, pregravid body mass 
index (BMI), prior lactation experience, and infant birth weight and length which were 
completed following infant birth. In addition, participants provided information about education 
and socioeconomic status. This information was confirmed by the women’s health care 
providers.  
1. Dietary intake 
Twenty-four hour dietary recalls were conducted during weeks two, three, and four 
weeks postpartum via telephone interview. A multi-pass interview approach was used in a 
standardized fashion to collect the recalls. The Nutrition Data System for Research (NDSR) 
software version 2017 (Minneapolis, MN, USA) was used to analyze the nutrient content of the 
foods/beverages reported. The tool also provided a dietary supplement assessment.   
2. Breast milk samples 
Samples were collected at two and four weeks postpartum in the participants’ homes. The 
women were asked to provide a breast milk expression from a single breast (emptying a full 
mammary gland by collecting all the milk from that breast) 21 using an electric breast pump. 
Before collecting the milk, participants were asked to fast for at least two hours and to collect the 
milk between 6 and 10 am. The sample was stored under refrigeration at the participant’s house 
(for a maximum of 24 hours) in the breast milk storage bag provided by the researcher. Samples 
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were transported on ice to the laboratory where the milk was warmed in a 37 °C water bath, 
manually gently swirled to mix, and ~15 mL aliquots were made in small glass vials with 
Teflon-lined caps and stored at -80 °C until analysis. Information including the breast pump 
brand used, exclusive breastfeeding, and use of formula for supplementation were also recorded. 
Samples were shipped overnight on dry ice to the Center for Drug Discovery, Northeastern 
University, Boston, MA and kept at -80°C until analysis. 
Sample analyses 
1. Dietary intake 
To perform a 24-h dietary recall, individuals were asked to recount all food, beverages 
and nutritional supplements consumed the day before the interview. Individuals were provided a 
food amounts booklet to assist them in assessing the portion sizes of food and beverages they had 
consumed. The period being recalled consisted of the 24 hours which went from midnight to 
midnight from the previous day. Nutrient data for the three dietary recalls performed were 
analyzed and averaged. 
2. Breast milk samples 
Breast milk samples were analyzed by liquid chromatography-mass spectrometry (LC-
MS) with a state of the art methodology established at the Center for Drug Discovery at 
Northeastern University, Boston, MA. Milk samples were thawed in a 37 °C water bath and 
vortexed at medium speed for 10 s at room temperature. Protein precipitation was carried out 
with chilled acetonitrile and PBS (pH 7.4) and the addition of an internal standard mixture, 
followed by centrifugation (14,000 × g, 5 min, 4°C). The resulting supernatant was diluted with 
four volumes of 5% phosphoric acid followed by solid phase extraction using OASIS HLB 
reverse-phase chromatography cartridges (Waters Corp., Mildford, MA) which were previously 
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rinsed with methanol and water prior to loading the diluted samples. Loaded cartridges were 
washed with 40% aqueous methanol prior to eluting the absorbed lipids with acetonitrile. The 
acetonitrile fraction was evaporated to dryness under nitrogen, reconstituted in ethanol, vortexed 
and sonicated, and centrifuged prior to LC-MS analysis. The autosampler was kept at 4 °C to 
prevent analyte degradation. A TSQ Quantum Ultra triple quadrupole mass spectrometer 
(Thermo Electron, San Jose, CA) with an Agilent 1100 liquid chromatograph (Agilent 
Technologies, Wilmington, DE) at the front end was used for identification and quantification. 
Separation of analytes was carried out using an Agilent 2.1x50 mm, 5 μm Zorbax SB-CN 
column22,23 with gradient elution using 10 mM ammonium acetate (pH 7.3) and methanol (flow 
rate, 0.5 ml/min). Elution of fatty acids was achieved while the mass spectrometer was in 
negative ionization mode, followed by a change in the mass spectrometer to positive ionization 
mode for elution of ethanolamine and glycerol esters. Eluted peaks were ionized via atmospheric 
pressure chemical ionization in multiple reaction monitoring mode. Deuterated internal standards 
were used to derive a standard curve for each analyte and concentrations (ng/mL) of breast milk 
were calculated. Each sample was analyzed in triplicate and concentrations were averaged.   
Statistical analyses 
Statistical analyses were performed using SAS by SAS Institute, Inc., version 9.4 (Cary, 
NC). The level of significance was set at ≤ 0.05. Descriptive statistics (mean, standard deviation, 
and range) were used for numeric variables. Pearson correlations were used to evaluate the 







One hundred thirty-one potential participants were invited to the study from which 31 
consented to participate. Seven women dropped out during the study, so the final number of 
participants was 24. Table 5.1 provides participants’ characteristics. Lactating women in the 
study were between 18 and 39 years old.  Seventy-five percent (n = 18) of infants were delivered 
vaginally and a third (n = 8) of infants were girls. The rates of infants being exclusively breastfed 
were 83% (n = 20) at 2 weeks and 67% (n = 16) at 4 weeks postpartum. 
       Table 5.1. Maternal-Infant Characteristics (n = 24) 
Characteristic 
Mean ± SD or  
% (frequency) 
Range 
Maternal Characteristics   
Age (y) 






Gestational age at delivery (weeks) 




Some high school 
High school 
Some college 








30.5 ± 5.0 
28.0 ± 5.8 
 
 71 (17) 
17 (4) 
  8 (2) 
  4 (1) 
39.2 ± 1.3 
 
29 (7) 
  71 (17) 
 
  4 (1) 
  4 (1) 
21 (5) 
25 (6) 
  46 (11) 
 
21 (5) 
  79 (19) 
 
13 (3) 
  88 (21) 
18.0 – 39.0 






37.0 – 41.0 













Mean ± SD or  
% (frequency) 
Range 
Mode of delivery 
Vaginal 
Cesarean 
Birth weight (lbs) 
Feeding type 
Exclusively breastfed 
Supplemented with formula 
 
  75 (18) 
25 (6) 
7.4 ± 0.8 
2 weeks 





5.5 – 9.2 
4 weeks 
 67 (16) 
33 (8) 
BMI, body mass index; WIC, Woman, Infant, and Children Special Supplemental 
Nutrition Program 
Table 5.2 presents the daily dietary intake of participants. Dietary intake of DHA was 98 
± 162 mg and EPA was 49 ± 91 mg; the combined DHA+EPA was 147 ± 251 mg. The mean for 
these two LCPUFAs was inflated because two participants were consuming a high amount in 
relation to the majority of the other participants. One participant was consuming 186 mg EPA 
and 377 mg DHA and the other participant was consuming 428 mg EPA and 751 mg DHA; 
amounts surpassing the recommendation of consuming at least 200 mg of DHA or 250 mg of 
EPA+DHA per day. These amounts were achieved in part by consuming salmon, a very well 
know source of EPA+DHA which provides 1,200-2,400 mg/4 ounces,24 in addition to other food 
sources of DHA. The mean value without including these two participants was 26 ± 27 mg of 
EPA and 56 ± 52 mg of DHA per day. The amount of linoleic acid (LA) consumed (17 ± 5 g) 
was 10 times higher than that of α-linolenic acid (ALA) (1.7 ± 0.7 g).  
Only 17% (n = 4) of women in the study were meeting the recommended DHA intake of 
at least 200 mg/day. When adding supplemental DHA, the number of women meeting the 
recommendation increased to 38% (n = 9) (Table 5.3). Only 42% of the study subjects (n = 10), 





Table 5.2. Daily Dietary Intake by Lactating Women (n = 24) 
Nutrient 
Average daily intake 
(mean ± SD) 
Range 
(Min – Max) 
Energy (kcal) 2,013 ± 514  1,057 – 3,188 
Protein (g)    76 ± 25              34 – 118 
Carbohydrate (g)  245 ± 60  129 – 342 
Total fat (g)    85 ± 30   39 – 164 
Saturated fat (g)    28 ± 13 12 – 67 
Polyunsaturated fat (g)  19 ± 6   8 – 31 
Linoleic acid (g) – LA  17 ± 5   7 – 28 
α-Linolenic acid (g) – ALA     1.7 ± 0.7  0.4 – 3.0 
Arachidonic acid (mg) – ARA   155 ± 73    36 – 310 
Eicosapentaenoic acid (mg) – EPA    49 ± 91             1.3 – 428 
Docosahexaenoic acid (mg) – DHA      98 ± 162   1.7 – 751 
n-6/n-3**  10 ± 4    6 – 23 
**n-6/n-3 = (LA + AA) / (ALA + EPA + DHA) 
            Table 5.3. Consumption of DHA by Lactating Women (n = 24) 
DHA Source 
< 200 mg DHA/day 
mean ± SD (n) 
≥ 200 mg DHA/day 
mean ± SD (n) 
Dietary DHA 45 ± 38 (20) 364 ± 280 (4) 
Dietary + Supplemental DHA 61 ± 59 (15) 381 ± 216 (9) 
Lactating women are advised to consume at least 200 mg/day of DHA10 
DHA, docosahexaenoic acid. 
 
 Table 5.4 shows the concentrations of the precursor LCPUFA (DHA, EPA, and ARA) 
and their derived EC metabolites (DHEA, DHG, EPEA, EPG, AEA, and AG) in breast milk. 
Arachidonic acid comprised 61% of the LCPUFA fraction followed by DHA and EPA 
comprising 28% and 11%, respectively. For each group, the glycerol-derivatives were present in 








Table 5.4. Fatty Acids and its Derived EC and EC-like Metabolites in Breast Milk (n = 24) 
Metabolite 
Mean ± SD 
ng/mL 
Range 
(Min – Max) 
n-3 DHA 
      DHEA 
      DHG 
2159.87 ± 3076.02 
0.09 ± 0.05 
  752.85 ± 1123.40 
   130.50 – 14172.50 
0.04 – 0.22 
    46.35 – 4674.00 
n-3 EPA 
      EPEA* 
      EPG 
  844.16 ± 2268.62 
0.09 ± 0.12 
42.07 ± 71.87 
     13.81 – 10835.50 
              0.01 – 0.47 
    0.84 – 296.10 
n-6 ARA 
      AEA 
      AG 
4712.24 ± 8281.88 
0.11 ± 0.12 
233.31 ± 299.11 
    433.00 – 37150.00 
              0.04 – 0.60 
    16.20 – 1106.00 
Data are presented by showing the precursor fatty acid followed by its derived 
endocannabinoid metabolites. 
*Some values were below the standard curve. 
DHA, docosahexaenoic acid; DHEA, docosahexaenoyl ethanolamide; DHG, 
docosahexaenoyl glycerol; EPA, eicosapentaenoic acid; EPEA, eicosapentaenoyl 
ethanolamide; EPG, eicosapenaenoyl glycerol; ARA, arachidonic acid; AEA, 
Anandamide; AG, arachidonoyl glycerol. 
 To evaluate the relationships between the dietary LCPUFAs and the concentrations in 
breast milk for the fatty acids and their derived EC, we performed log transformation of the data. 
Table 5.5 shows significant correlations for DHA and EPA only. There was a positive correlation 
between dietary DHA and the DHA (r = 0.50, p ≤ 0.05), DHEA (r = 0.66, p ≤ 0.05), and DHG (r 
= 0.46, p ≤ 0.05) in the breast milk. Dietary EPA was only correlated to the EPA in breast milk (r 
= 0.41, p ≤ 0.05), but not with the derived EC. No correlations were found between dietary ARA 
and the fatty acid and EC concentrations in the breast milk.  
Table 5.5. Significant Correlations between Dietary Long-Chain Fatty Acids and the 





DHAd* – DHA  
DHAd* – DHEA 







EPAd* – EPA 0.41 0.0454 
*From diet. 
DHA, docosahexaenoic acid; DHEA, docosahexaenoyl ethanolamide; DHG, 





 This study, to the best of our knowledge, is the first report evaluating the relationships 
between maternal dietary intake of LCPUFAs and EC and EC-like metabolites in human breast 
milk. Provided that the EC may play a role in infant feeding behavior,17 maternal intake of 
LCPUFAs during lactation is important to ensure that breast milk is supplying the infant not only 
with sufficient quantities for adequate development, but also to provide precursor fatty acids for 
EC metabolism. On average, lactating women in the present study were not consuming adequate 
amounts of DHA (98 mg/day) to meet the dietary recommendation to consume at least 200 mg of 
DHA per day during lactation.10 That is, lactating women in this study were only receiving 49% 
of the recommended amount. The majority of women (83%, n = 20) were not meeting that 
recommendation. When amounts from supplementation were included, the percentage only 
decreased by 21%, meaning that 62% (n = 15) of women still failed to meet the DHA 
recommendation. This observation with American women is in contrast to a study conducted 
with Canadian women where it was concluded that women who consumed a supplement with 
DHA were 11 times more likely to meet the DHA recommendation for lactating women.25 
However, in this Canadian study women were consuming 186 mg/day of DHA from the diet 
(major food sources were seafood, fish, and seaweed products), an amount 1.9 times higher than 
the amount consumed by women in our study. When considering EPA+DHA combined, women 
in this population were only consuming 147 mg/day which is below the amount recommended 
by the Dietary Guidelines for Americans11 that suggest consuming an average of 250 mg/day of 
EPA+DHA. Unfortunately, our results are in line with the last report by the National Health and 
Nutrition Examination Survey 2013-201426 which indicated that women of childbearing ages 20-
39 years old in the United States are only consuming 25 mg of EPA and 55 mg of DHA daily. 
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On the other hand, for the essential fatty acids LA and ALA, amounts consumed (17 and 1.7 g, 
respectively) exceeded the adequate intake recommended by the Institute of Medicine which is 
13 g/d for LA and 1.3 g/d for ALA.9 The n-6/n-3 ratio was 10:1 which is typical of the American 
diet that is characterized by a higher consumption of n-6 than n-3 fatty acids.26 
 Our data showed a positive correlation between dietary DHA and EPA and the amounts 
of these LCPUFAs present in the breast milk. Our results are in agreement with previous 
research that found that LCPUFAs in breast milk reflect maternal intake and/or supplementation. 
In a study by Jensen and colleagues (2005),27 lactating women who were supplemented during 
four months with 200 mg DHA/day demonstrated higher levels of DHA in their breast milk 
compared to the control group who consumed a placebo. Another study by Sherry et al. (2015)28 
supplemented lactating women with a placebo, a low-dose DHA (200 mg/day), or a high-dose 
DHA (400 mg/day). After six weeks of supplementation, both DHA doses increased the DHA 
content of the breast milk by 50% and 123% (low and high dose, respectively) from baseline. 
Eicosapentaenoic acid was also increased over time, although no significant differences were 
found among the intervention groups.      
This study is the first to explore the relationships between dietary LCPUFAs and the EC 
in breast milk. Our data indicates that dietary DHA is positively correlated with its derived EC, 
DHEA and DHG only. For dietary EPA and ARA, no correlations were found with its derived 
EC (EPEA-EPG and AEA-AG, respectively) in the breast milk. Research to date has been 
focused on evaluating circulating and tissue levels (e.g. brain, liver, and small intestine) in 
response to dietary interventions in animal models. In a study by Berger et al. (2001),29 piglets 
were fed diets with and without ARA and DHA in similar quantities to those found in porcine 
milk during 18 days. Levels of the ehanolamide-derivatives from ARA and DHA were evaluated 
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in the piglet’s brain. For piglets consuming the diet containing ARA and DHA, brain levels of 
the ethanolamide-derivatives (AEA, DHEA, and EPEA) were increased. Similarly, Artmann et 
al. (2008)19 demonstrated in a rat model that short term consumption (one week) of diets 
resembling human diets modulate LCPUFA ethanolamide-derivatives levels in brain, liver, and 
small intestine. In another study using mice, Wood et al. (2010)18 evaluated the effect of a two-
week DHA-diet (containing DHA and EPA from fish oil) on the EC levels in brain and plasma. 
After supplementation, the DHEA significantly increased in mouse’s brain and plasma but DHG 
did not change. Eicosapenaenoyl glycerol was also increased in both tissues. Likewise, the DHA-
diet significantly increased the ratios of DHEA/AEA and DHG/AG.  
Research data18,19,29 have shown that dietary LCPUFAs can modulate tissue levels of 
bioactive compounds (i.e. EC and EC-like metabolites). Our results showing that DHA 
ethanolamide-derivatives in breast milk are associated with dietary DHA permit to hypothesize 
that maternal dietary interventions proving LCPUFAs could modulate EC levels in breast milk. 
Research studies can be designed based on our results to confirm this hypothesis. It could be also 
speculated that supplementation with LCPUFAs during lactation will elicit changes in the EC 
concentrations in the breast milk, not only for the DHA-derivatives but also for the other EC-like 
metabolites in both glycerol and ethanolamide groups. In the present study, it could be possible 
that EPA acted as a substrate for synthesis of DHA, followed by DHEA and DHG synthesis 
rather than as a substrate for EPEA and EPG synthesis. This could have prevented us from 
finding a significant correlation between the dietary EPA and derived EC in the breast milk. 
Biosynthesis rates in the mammary gland may differ for each EC group, ethanolamides and 
glycerols. Our results indicated a stronger correlation between dietary DHA and DHEA (r = 
0.66) than dietary DHA and DHG (r = 0.46). These observations suggest that there is a 
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preference for DHEA synthesis rather than for DHG or that the presence of other entourage 
metabolites (data not shown), which exert cannabimimetic effects,30 may interfere with the 
activity of one over another presumably by acting a as substrates for enzymatic activity, reducing 
cellular uptake and/or degradation, or by affecting binding activity to the receptors.12,31  
5.5 Limitations 
The study had limitations. Dietary data were collected using 24-h dietary recalls and this 
could have prevented us from identifying dietary patterns regarding consumption of food sources 
that provide LCPUFAs. These three days of intake may not have captured typical consumption 
of these nutrients. We recommend that future studies include food frequency questionnaires, with 
specific fish types included, in addition to 24-h dietary recalls to better estimate DHA dietary 
intakes. 
5.6 Conclusion 
Our study explored the relationships between dietary LCPUFAs and the EC metabolites 
in breast milk. We have provided evidenced that i) lactating women are not achieving 
recommended amounts of DHA, and ii) dietary DHA is associated with levels of its derived EC 
in breast milk. Although the roles of the different EC metabolites have not been fully elucidated, 
we have demonstrated that they are present in the breast milk and are associated with dietary 
precursors. These observations lead to proposed questions. Are these EC metabolites present in 
breast milk to support infant development?  Do dietary LCPUFAs modulate the EC tone in 
breast milk? Could DHA-derivatives be more susceptible to changes in the diet than their 
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SUMMARY AND CONCLUSIONS 
 The present study has demonstrated that endocannabinoids and endocannabinoid-
constituents are present in human breast milk. Using a state of the art lipidomic methodology of 
analysis we have identified and quantified fifteen constituents of the endocannabinoid 
metabolome that includes three long-chain polyunsaturated fatty acids. Our data sets the ground 
for designing future studies to help elucidate not only the mechanisms by which 
endocannabinoids are synthesized and utilized in the mammary gland, but also which role 
endocannabinoids play in infant health and development.  In the two different populations 
studied, both with different dietary patterns, endocannabinoids have been identified in the breast 
milk. Considering this observation, we propose that a research study can be developed to 
evaluate if the levels of endocannabinoids in the breast milk respond to maternal dietary 
supplementation of long-chain fatty acids. Although we conducted the studies at different 
lactation stages (1/2-1 month and 4-6 months of lactation), both studies showed that different 
endocannabinoid metabolites are present in the breast milk regardless of the stage. However, we 
hypothesize that colostrum may have increased levels of endocannabinoids provided that they 
may play a role in establishing the suckling response of the newborn. Taking the three studies 
presented in this umbrella study, we have been able to raise questions regarding the dynamics of 
the endocannabinoid metabolome of human breast milk that can be used to determine the future 
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